Bayer

Bayer’s asundexian first FXIa inhibitor approved by U.S. Food and Drug Administration for secondary stroke risk reduction

10 Nov 2026

Sevabertinib approved in China as first-line treatment for patients with HER2-mutant non-small cell lung cancer

04 Nov 2026

Bayer AG Third Quarter 2026 Results and Media Update

03 Nov 2026

Bayer increases sales and EBITDA before special items in the third quarter, improves full-year outlook

03 Nov 2026

Monsanto unanimously wins first Roundup™ trial since U.S. Supreme Court decision

30 Oct 2026

Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review

26 Oct 2026

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

24 Oct 2026

Articles tagged with 'doccheck' | Bayer

22 Oct 2026

AskBio Announces 5 Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress

22 Oct 2026

EU and UK Risk Falling Further Behind Global Agricultural Competitors, Weakening Strategic Autonomy

15 Oct 2026

View details about the software product Informachine News Trackers